-
BridgeBio Pharma Gets First FDA-Approval For Rare Genetic Metabolic Disorder
Monday, March 1, 2021 - 6:17am | 198BridgeBio Pharma Inc (NASDAQ: BBIO) and affiliate Origin Biosciences Inc have received the FDA approval for Nulibry (fosdenopterin) Injection to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type-A. MoCD is a rare metabolic...